Benefits of Sarissa Biosensors:
- They are so small and streamlined they do not damage brain tissue when obtaining results - producing more accurate and reliable results in comparison to conventional biosensors.
- The accuracy of the sensors is improved as they can locate the exact point where the purines are released.
- They produce a strong signal producing the ability to measure even the smallest levels of purines.
What we do
We specialise in the development and production of novel biosensors for the measurement of neuroactive chemicals during in vitro and in vivo studies for research and clinical diagnostic applications. Sarissa has a philosophy of innovation and continual improvement of its products to bring the latest in biosensing technology to the scientific research community.
Our (short) history
Formed in November 2002. Sarissa Biomedical Ltd's first product, sarissaprobe®-ATP, was launched at Neuroscience, in San Diego (October, 2004) and has since been sold to neuroscience researchers in the UK, USA, Canada and Japan. Further products, sarissaprobe®-ADO and sarissaprobe®-INO for the measurement of adenosine and inosine respectively were launched in 2005. This range has recently been further extended to include sarissaprobe®-ACH (for acetylcholine) and sarissaprobe®-GLU (for glutamate). In collaboration with Sycopel International Ltd, we now offer a dual potentiostat specifically designed for use with sarissaprobe® biosensors.
Product Development
Sarissa Biomedical Ltd was founded with the principal of product development at the forefront of our activities. We pride ourselves on continuous evolution of our products in order that we can bring new sensors to market and ensure that all of our sensors out perform their rivals.
Our Technology
Sarissa is developing a range of minimally invasive, microelectrode electrochemical sensors for the measurement of the purines and other neurochemicals, as indicators of neurological activity / disorders and has a product design platform that offers exquisite sensitivity, coupled with a broad linear activity range and high levels of accuracy and reproducibility. These biosensors are designed for in vitro and in vivo studies for research and diagnostic applications.
Crucial to the Sarissa's highly differentiated technology are the unique methods by which active enzyme-based layers are deposited onto the surface of the sensor. In the case of the ATP sensor (sarissaprobe®-ATP) the enzyme matrix includes glycerol kinase and glycerol-3-phosphate oxidase, deposited onto the surface of a Pt/Ir microelectrode.
Journal of Neuroscience
